Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.31 USD | +3.44% | +0.48% | -21.32% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company has a low valuation given the cash flows generated by its activity.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company sustains low margins.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.32% | 2.24B | C+ | ||
+48.79% | 780B | C+ | ||
+41.76% | 627B | B | ||
+19.43% | 334B | B- | ||
+7.18% | 296B | C+ | ||
+17.60% | 244B | B+ | ||
-0.41% | 217B | A+ | ||
+11.54% | 214B | B- | ||
+4.53% | 161B | C+ | ||
-3.92% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BHC Stock
- Ratings Bausch Health Companies Inc.